by Richard Daverman, PhD
March 6, 2014 -- Shanghai-based PhageLux has received an investment from WuXi PharmaTech Healthcare Fund, the investment arm of CRO WuXi PharmaTech. PhageLux uses phages to solve bacterial problems in fields such as crop disease, animal health, food safety and general sanitary. This year, PhageLux will begin work on human health issues. PhageLux has taken offices in the ChinaBio® Accelerator located in the Biotech VC Plaza at Shanghai’s Zhangjiang Hi-Tech Park. More details....
Stock Symbol: (NYSE: WX)
Help employers find you! Check out all the jobs and post your resume.